

COVID-19 Update for CDHA Members

September 15, 2022

CDHA is Here to Help

Read our latest updates: www.cdha.ca/COVID19
Email us: alerts@cdha.ca

Dear member,

With school back in session and the highly transmissible Omicron BA.4 and BA.5 subvariants becoming the dominant COVID-19 strain, a rise in COVID-19 cases is anticipated. CDHA encourages you to stay attentive over the course of the next few months.

Approval of first bivalent COVID-19 vaccine

Health Canada has [approved](#) an adapted version of the Moderna Spikevax COVID-19 vaccine, known as a bivalent vaccine, which targets the original COVID-19 virus from 2019 and the Omicron (BA.1) variant. The National Advisory Committee on Immunization (NACI) has also released their [full recommendations](#) and [summary](#) on the use of bivalent vaccines. It has been found to generate a good immune response against the Omicron BA.4 and BA.5 subvariants.

Vaccination programs for Fall 2022

The Council of Chief Medical Officers of Health (CCMOH) has released a [statement](#) on the current vaccination status of the Canadian population, the ongoing risk factors of COVID-19 infection and the recommendations for Fall vaccination programs.

Counterfeit rapid antigen covid tests

The Government of Canada has issued a safety alert that counterfeit COVID-19 antigen rapid test kits have been found in Ontario. Please click [here](#) for more details.

Rate of myocarditis post COVID-19 vaccine and COVID-19 infection

The University of Waterloo School of Pharmacy released a [Frequently Asked Questions](#) resource with respect to the incidence of myocarditis and pericarditis after COVID-19 infections and COVID-19 vaccines.

CDHA encourages you to continue to assess your personal situation and environment to determine the steps needed to protect yourself and others.

~

*Please be well and take care of yourselves.
We can all do our part to protect the health of ourselves and others.*